An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria
Status: | Terminated |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | Any - 75 |
Updated: | 12/7/2018 |
Start Date: | July 2012 |
End Date: | June 2018 |
An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection
This study will evaluate the clinical efficacy and safety of a combination of leflunomide and
orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the
purpose of preventing Polyoma BK viremia and Nephropathy that could lead to kidney transplant
loss from viral damage, acute rejection or both.
orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the
purpose of preventing Polyoma BK viremia and Nephropathy that could lead to kidney transplant
loss from viral damage, acute rejection or both.
This is a multicenter, randomized trial that will evaluate the effect of a combination of
leflunomide and orotic acid for the treatment of Polyoma BK viruria. In this multicenter
trial, renal allograft patients with the diagnosis of Polyoma BK viruria as determined by a
viral level in the urine of 25 million or more copies/mL, and no detectable viremia, will
complete a screening visit (V1) to determine eligibility for the study based on
inclusion/exclusion criteria. Patients that meet the entrance criteria for this study will be
randomly assigned to one of two treatment groups at Visit (2) and enter a 4 month dosing
period.
leflunomide and orotic acid for the treatment of Polyoma BK viruria. In this multicenter
trial, renal allograft patients with the diagnosis of Polyoma BK viruria as determined by a
viral level in the urine of 25 million or more copies/mL, and no detectable viremia, will
complete a screening visit (V1) to determine eligibility for the study based on
inclusion/exclusion criteria. Patients that meet the entrance criteria for this study will be
randomly assigned to one of two treatment groups at Visit (2) and enter a 4 month dosing
period.
Inclusion Criteria:
1. Patients, 75 years of age or less, with the diagnosis of renal allograft Polyoma BK
viruria of 10 million or more copies/mL in their urine confirmed by PCR at the central
laboratory.
2. No viremia (viremia is defined as greater than 1,000 copies/ml plasma on two
consecutive tests two weeks or more apart as measured at the designated central
laboratory),
3. Serum creatinine <2.0 mg/dL
4. Hct > 30%
5. WBC > 3,500 x 103/L
6. Platelet count > 150,000 x 103/L
7. Normal values for ALT, AST and bilirubin; Alk Phos < 2 X upper limits of normal
8. No symptomatic cardiac, pulmonary, GI, hepatic or neurologic disease
9. No other active infections
10. Receiving CyA or Tacrolimus, Mycophenolate/Azathioprine + prednisone.
11. Is not pregnant as verified by a pregnancy test
Exclusion Criteria:
1. Is not able to comply with study procedures and dosing.
2. Has psychiatric instability.
3. Has an active systemic infection including Hepatitis B or C, HIV, or on anti-viral
therapy within seven days of entering the study. Note however, that the subjects may
be taking ganciclovir, valaciclovir, acyclovir and valganciclovir and therefore these
are not exclusionary antiviral medications.
4. Has BK viremia (viremia is defined as greater than 1,000 copies/ml plasma on two
consecutive tests two weeks or more apart as measured at the designated central
laboratory), or has had a single episode of BK viremia. (viremia is defined as greater
than 1,000 copies/ml plasma on two consecutive tests two weeks or more apart as
measured at the designated central laboratory or the local laboratory),
5. Has a cancer diagnosis within past five years with potential for recurrence.
6. Has received experimental drug within past 3 months.
7. Is receiving immune suppressive drug other than those listed above calcineurin
inhibitor, mycophenolate/azathioprine and +/- corticosteroid)
8. Is a woman of child bearing potential or is a male with female partner of child
bearing potential who is unwilling to use reliable contraception.
9. Has any neurologic abnormalities including peripheral neuropathy.
10. Is receiving concomitant therapy with drug known to have hepatotoxic risk.
11. Has known or suspected liver disease or current alcohol abuse.
We found this trial at
9
sites
Memphis, Tennessee 38104
Principal Investigator: Vinaya Rao, MD
Phone: 901-516-8078
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: Clifton Kew, MD
Phone: 205-996-2577
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
1 Tampa General Cir
Tampa, Florida 33606
Tampa, Florida 33606
(813) 844-7000
Principal Investigator: Rajendra Baliga, MD
Phone: 813-844-5692
Tampa General Hospital In a diverse city known for its rich culture and beautiful beaches,...
Click here to add this to my saved trials
Boston, Massachusetts 02215
Principal Investigator: Martha Pavlakis, MD
Phone: 617-632-9841
Click here to add this to my saved trials
Chicago, Illinois 60612
Principal Investigator: Edward Hollinger, MD
Phone: 312-563-4249
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
Chicago, Illinois
(312) 996-4350
Principal Investigator: Ignatus Tang, MD
Phone: 312-996-5695
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
Chicago, Illinois 60637
Principal Investigator: Michelle Josephson, MD
Phone: 773-834-0684
Click here to add this to my saved trials
Click here to add this to my saved trials
318 West Brandeis Avenue
Louisville, Kentucky 40202
Louisville, Kentucky 40202
Principal Investigator: Mary Eng, MD
Phone: 502-587-4106
Click here to add this to my saved trials